Literature DB >> 7915974

Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.

S Peifang1, G L Pira, D Fenoglio, S Harris, M G Costa, V Venturino, V Dessì, G Layton, J Laman, J G Huisman.   

Abstract

Recombinant virus-like particles (VLP), formed by the yeast Ty p1 protein, carrying the HIV gp120 V3 loop on their surface (V3-VLP) have been tested in vitro for immunogenicity and antigenicity by using VLP p1-specific human CD4+ T cell lines and clones. VLP-specific human T cell lines and clones were generated from normal individuals, indicating that VLP-specific precursor cells present in the peripheral lymphocyte pool can be induced to expand clonally upon antigen challenge in vitro, in the absence of previous immunization. It was also shown that V3-specific polyclonal antibodies enhance V3-VLP-induced activation of VLP-specific T cell clones. Antibody-dependent potentiation has been shown previously in other antigen systems, and it depends on enhanced uptake of complexed antigen by Fc receptor-positive antigen-presenting cells. Since in this case antigen is internalized by presenting cells as a complex, it can be inferred that a similar event of antibody-mediated antigen uptake can take place with V3-specific B cells, resulting in presentation by the B cells of T helper epitopes derived from processing of the VLP p1 moiety. This suggests that T helper cells specific for the carrier VLP p1 protein can be activated to provide help to V3-specific B cells in the presence of the appropriate antigen construct.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915974      PMCID: PMC1534850          DOI: 10.1111/j.1365-2249.1994.tb06095.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  55 in total

Review 1.  Carrier sequence selection--one key to successful vaccines.

Authors:  H M Etlinger
Journal:  Immunol Today       Date:  1992-02

Review 2.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.

Authors:  F Manca; L Walker; A Newell; F Celada; J A Habeshaw; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

4.  Selective functional depletion of HIV gp120 peptides complexed with MHC from antigen-presenting cells engaged with specific T lymphocytes.

Authors:  F Manca
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

Review 5.  B cells on the podium: regulatory roles of surface and secreted immunoglobulins.

Authors:  F Manca; D Fenoglio; A Kunkl; C Cambiaggi; G Li Pira; F Celada
Journal:  Immunol Today       Date:  1988-10

6.  Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Authors:  T J Palker; T J Matthews; A Langlois; M E Tanner; M E Martin; R M Scearce; J E Kim; J A Berzofsky; D P Bolognesi; B F Haynes
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

7.  Identification of human immunodeficiency virus (HIV) envelope type-specific T helper cells in an HIV-infected individual.

Authors:  C M Walker; K S Steimer; K L Rosenthal; J A Levy
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.

Authors:  J Goudsmit; C A Boucher; R H Meloen; L G Epstein; L Smit; L van der Hoek; M Bakker
Journal:  AIDS       Date:  1988-06       Impact factor: 4.177

10.  Galactose receptors and presentation of HIV envelope glycoprotein to specific human T cells.

Authors:  F Manca
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.